Skip to main content

Viridian Therapeutics

Viridian Therapeutics Inc is an American clinical-stage biopharmaceutical company focused on the discovery and development of potential best-in-class antibody treatments for serious autoimmune and rare diseases. The company utilizes its specialized antibody engineering platform to develop differentiated therapies targeting insulin-like growth factor-1 receptor (IGF-1R), prominently featuring clinical candidates such as veligrotug and VRDN-008 for thyroid eye disease and related autoimmune conditions. Its core operations encompass preclinical antibody discovery, protein engineering, clinical trial management, and biotechnology research. As a clinical-stage biopharmaceutical enterprise, the company generates minimal commercial revenue and finances its operations through public equity financing and capital market funding. Viridian Therapeutics holds an emerging position in targeted immunological therapies. The company is headquartered in Waltham, Massachusetts, United States, and its common stock trades on the Nasdaq Global Select Market.

6 of the funds FundTelligence covers report a position in Viridian Therapeutics.

Legal name
Viridian Therapeutics Inc
Sector
Health Care
Country
United States
Funds holding it
6

Funds holding Viridian Therapeutics

Loading...